Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von GraveDigger 

Bluebird Bio Inc. diskutieren

Bluebird Bio Inc.

WKN: A1W025 / Symbol: BLUE / Name: bluebird bio / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

1,41 €
-1,59 %

Buy Bluebird Bio Inc.

Buy Bluebird Bio Inc.

Buy Bluebird Bio Inc.

bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock.
Ratings data for BLUE provided by MarketBeat

Einschätzung Sell
Rendite (%) -53,33 %
Kursziel 2,76
Veränderung
Endet am 03.04.24

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Morgan Stanley from $4.00 to $3.00. They now have an "underweight" rating on the stock.
Ratings data for BLUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -58,39 %
Kursziel 12,18
Veränderung
Endet am 08.11.24

bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Raymond James from $10.00 to $13.00. They now have an "outperform" rating on the stock.
Ratings data for BLUE provided by MarketBeat

bluebird bio, Inc. (NASDAQ: BLUE) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for BLUE provided by MarketBeat

bluebird bio, Inc. (NASDAQ: BLUE) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for BLUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -50,73 %
Kursziel 11,15
Veränderung
Endet am 11.12.24

bluebird bio, Inc. (NASDAQ: BLUE) had its price target raised by analysts at Bank of America Co. from $11.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for BLUE provided by MarketBeat

bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.
Ratings data for BLUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -44,98 %
Kursziel 6,49
Veränderung
Endet am 12.12.24

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Robert W. Baird from $10.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for BLUE provided by MarketBeat

Einschätzung Buy
Rendite (%) 13,07 %
Kursziel 4,55
Veränderung
Endet am 21.12.24

bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Bank of America Co. from $12.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for BLUE provided by MarketBeat